title: Facilitating tailored therapeutic strategies for glioblastoma through an orthotopic patient-derived xenograft platform.
abstract: Despite years of research into its pathobiology and continuing clinical trials for novel therapies, the prognosis for patients with glioblastoma (GBM) remains dismal. An important obstacle against treatment efficacy may be a high degree of intra- and inter-tumoral heterogeneity within GBMs, which may be caused by the presence of self-renewing GBM stem cells (GSCs). Recent advances in multi-omics technology introduce new possibilities for applying personalized strategies to GBM therapy. As drug discovery is accelerating with the transition from non-selective, cytotoxic therapy to a precision, targeted approach, the appropriate in vivo platform for GBM is critical for validating drug targets and prioritizing candidates for clinical studies, for co-development of companion diagnostics and, ultimately, for drug approval. Here we will describe GBM orthotopic patient-derived xenografts (PDXs) as more useful, clinically relevant resources for individually tailored strategies for GBM.
authors.affiliation: Research Institute for Future Medicine, Institute for Refractory Cancer Research and Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea.
authors.forename: Hye Won
authors.initials: HW
authors.lastname: Lee
authors.affiliation: Institute for Refractory Cancer Research, Samsung Medical Center and Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea.
authors.forename: Kyoungmin
authors.initials: K
authors.lastname: Lee
authors.affiliation: Institute for Refractory Cancer Research, Samsung Biomedical Research Institute, Samsung Medical Center and Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea.
authors.forename: Dong Geon
authors.initials: DG
authors.lastname: Kim
authors.affiliation: Institute for Refractory Cancer Research and Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea.
authors.forename: HeeKyoung
authors.initials: H
authors.lastname: Yang
authors.affiliation: Institute for Refractory Cancer Research, Samsung Medical Center, Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University and Departments of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea nsnam@skku.edu.
authors.forename: Do-Hyun
authors.initials: DH
authors.lastname: Nam
mesh_terms: D000818:Animals; D001932:Brain Neoplasms; D005909:Glioblastoma; D006801:Humans; D057285:Precision Medicine / Q000379:methods* / Q000639:trends; D023041:Xenograft Model Antitumor Assays / Q000379:methods*